T Cell News and Research

Latest T Cell News and Research

Political ripples of overhaul remain uncertain

Lawmakers received mixed receptions at home after last week's vote, and speculation continues to swirl about how the health overhaul will play out in November's midterm elections.

30 Mar 2010

LCT receives approval for New Zealand Phase II human trial of DIABECELL

Living Cell Technologies Limited, a global company pioneering the development of a cell implant to treat diabetes, today announced that it has received approval to advance to the next phase of its New Zealand Phase II human clinical trial with its groundbreaking DIABECELL®. The approval follows a positive assessment from the New Zealand Data Safety and Monitoring Board of the first four patients to receive its DIABACELL® implants.

30 Mar 2010

NexMed files IND with FDA for Phase II trial of PrevOnco for HCC

NexMed, Inc, a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the Company has filed an Investigational New Drug (IND) application with the U.S. Food & Drug Administration (FDA) for a Phase II trial of its recently acquired cancer drug candidate PrevOnco™, in combination with doxorubicin in patients with advanced, unresectable hepatocellular carcinoma (HCC). The FDA has 30 days to comment on the IND before NexMed can proceed with human testing.

29 Mar 2010

Enrollment complete in Gemin X Pharmaceuticals' Phase 2 clinical trial of obatoclax for SCLC

Gemin X Pharmaceuticals, a clinical stage biopharmaceutical company developing novel, targeted cancer therapeutics, today announced the completion of patient enrollment in a Phase 2 clinical trial of the Company's lead product candidate obatoclax (GX15-070) for the treatment of extensive-stage small cell lung cancer (SCLC). The trial is designed to evaluate the efficacy and safety of obatoclax, a novel pan Bcl-2 inhibitor, in combination with standard chemotherapy for the first-line treatment of patients with SCLC.

29 Mar 2010

Helmholtz Zentrum München, SIRION BIOTECH partner to develop new therapeutic approaches against lymphoid tumors

Helmholtz Zentrum München has launched a new cooperative project with SIRION BIOTECH GmbH in Martinsried to develop new therapeutic approaches against lymphoid tumors. With a two-year grant from the Federal Ministry for Economics and Technology, the two partners will seek to further develop lentiviral vector systems to better understand the disease mechanisms of this cancer form and to devise approaches for treatment.

29 Mar 2010

High fructose corn syrup linked to skyrocketing rates of obesity

According to the Centers for Disease Control and Prevention, the rates of obesity in the United States have skyrocketed since the introduction of high fructose corn syrup in 1970. In that time, obesity rates have gone from 15 percent of the U.S. population to roughly one-third.

29 Mar 2010

Inovio Biomedical's total revenue increased to $2.6M for quarter ended December 31, 2009

Inovio Biomedical Corporation today reported financial results for the quarter and year ended December 31, 2009.

29 Mar 2010

New insights on events that lead to immortalized cells

Researchers at Umeå University can now show that cells that grow forever get this capacity through gradual changes in the expression of genes that govern the repair of DNA damage and regulate growth and cell death. The research also shows that activation of the enzyme complex telomerase, which is necessary for unlimited growth, occurs late in this process.

29 Mar 2010

FT and GGT enzymes can be promising targets for treatment of lung cancer

A research team at the Sahlgrenska Academy at the University of Gothenburg, Sweden, has shown in a study that two closely related enzymes could be targets for the treatment of lung cancer. The discovery was made when the researchers blocked the production of the two enzymes in transgenic mice. This resulted in inhibition of cell growth, fewer tumours and greater survival among the mice.

29 Mar 2010

New Prestige Antibodies powered by Atlas Antibodies added to Sigma Life Science's portfolio

Sigma® Life Science, the innovative biological products and services brand of Sigma-Aldrich®, today announced that it has added 2,200 new Prestige Antibodies® powered by Atlas Antibodies to its industry-leading portfolio.

From Atlas Antibodies AB 29 Mar 2010

Scientists link gene expression profiling effort to identify potential novel therapeutic for ALS

In an article published in Nature Genetics today, scientists at the ALS Therapy Development Institute describe how they have linked an unbiased gene expression profiling effort to the identification and successful preclinical testing of a potential novel therapeutic for amyotrophic lateral sclerosis.

29 Mar 2010

Cortex signs agreement to sell certain AMPAKINE compounds to Biovail

Cortex Pharmaceuticals, Inc. announced that it has entered into an agreement with Biovail Laboratories International SRL in which Biovail acquired certain AMPAKINE compounds and the rights to the patent filing for respiratory depression and vaso-occlusive crises associated with sickle cell disease.

29 Mar 2010

People with multitasking ability can safely drive while chatting on cell phone

A new study from University of Utah psychologists found a small group of people with an extraordinary ability to multitask: Unlike 97.5 percent of those studied, they can safely drive while chatting on a cell phone.

29 Mar 2010

UAB researchers discover first bio-marker for MS

Researchers at the University of Alabama at Birmingham have found the first bio-marker for multiple sclerosis that might predict which patients will respond to a standard therapy and which will not.

29 Mar 2010

Two-drug combination destroys precancerous colon polyps

A two-drug combination destroys precancerous colon polyps with no effect on normal tissue, opening a new potential avenue for chemoprevention of colon cancer, a team of scientists at The University of Texas M. D. Anderson Cancer Center reports in the advance online edition of the journal Nature.

29 Mar 2010

Researchers develop tiny chemical sensors to diagnose disease and track its progress

Tiny chemical sensors implanted into patients could help diagnose disease and track its progress, following a development by scientists.

29 Mar 2010

ER stress response is major driver of insulin resistance, say researchers

Biologists have long known that an enzyme called the PI 3-kinase is a crucial actor in the main molecular pathway for insulin signaling in cells. Researchers at Joslin Diabetes Center now have uncovered startling evidence that one of the proteins in this enzyme also drives a pathway with an opposite result-triggering a stress response that leads to insulin resistance.

29 Mar 2010

TB-causing bacteria can hijack fat metabolism to drive progression of the disease

The factors instrumental in triggering latent tuberculosis infection to progress into active disease have long remained elusive to researchers. New insight into the mystery is provided by Professor David Russell, speaking at the Society for General Microbiology's spring meeting in Edinburgh today. His work could help develop innovative strategies for treating the disease.

29 Mar 2010

New approach may circumvent lost response in insulin due to obesity

Researchers at Children's Hospital Boston have identified a new strategy for treating type 2 diabetes, identifying a cellular pathway that fails when people become obese. By activating this pathway artificially, they were able to normalize blood glucose levels in severely obese and diabetic mice. Their findings will be published online by Nature Medicine on March 28.

29 Mar 2010

Strong lobbying efforts by tanning bed industry a barrier to passage of legislation

Researchers from Boston University School of Medicine (BUSM) have found that when attempting to pass tanning bed legislation, successful advocates collaborate with local and national organizations and lobbyists and have direct contact with the sponsoring legislator to aid in the passage of the bill. These findings, which appear on-line in the Journal of the American Academy of Dermatology, also identify strong lobbying efforts by the tanning bed industry as the biggest barrier to passing tanning bed legislation.

27 Mar 2010

T Cell News and Research

Latest T Cell News and Research

Political ripples of overhaul remain uncertain

LCT receives approval for New Zealand Phase II human trial of DIABECELL

NexMed files IND with FDA for Phase II trial of PrevOnco for HCC

Enrollment complete in Gemin X Pharmaceuticals' Phase 2 clinical trial of obatoclax for SCLC

Helmholtz Zentrum München, SIRION BIOTECH partner to develop new therapeutic approaches against lymphoid tumors

High fructose corn syrup linked to skyrocketing rates of obesity

Inovio Biomedical's total revenue increased to $2.6M for quarter ended December 31, 2009

New insights on events that lead to immortalized cells

FT and GGT enzymes can be promising targets for treatment of lung cancer

New Prestige Antibodies powered by Atlas Antibodies added to Sigma Life Science's portfolio

Scientists link gene expression profiling effort to identify potential novel therapeutic for ALS

Cortex signs agreement to sell certain AMPAKINE compounds to Biovail

People with multitasking ability can safely drive while chatting on cell phone

UAB researchers discover first bio-marker for MS

Two-drug combination destroys precancerous colon polyps

Researchers develop tiny chemical sensors to diagnose disease and track its progress

ER stress response is major driver of insulin resistance, say researchers

TB-causing bacteria can hijack fat metabolism to drive progression of the disease

New approach may circumvent lost response in insulin due to obesity

Strong lobbying efforts by tanning bed industry a barrier to passage of legislation

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in